Plain-English translation of NCT06844383 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication that targets cancer cells with specific genetic mutations, to see if it works better alone or when combined with another hormone therapy. You would be eligible if your advanced prostate cancer has continued to grow despite previous treatment and if testing shows you have one of several specific mutations in your cancer cells.
Prostate cancer that has spread and stopped responding to standard hormone treatments is very difficult to manage. This study is exploring whether this medication might be more effective for patients whose cancer has these particular genetic mutations, offering a new option after other treatments have stopped working.
You likely qualify if…
You likely don't qualify if…
You would take one or two daily medications by mouth in continuous 28-day cycles. You'll be randomly assigned to receive either the new medication alone or combined with another hormone therapy. Throughout the study, you'll have regular visits for blood tests, imaging scans to monitor your cancer, and check-ups to see how you're doing, even if your PSA levels (a cancer marker) rise, unless your cancer worsens significantly.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States